Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer (vol 5, e225394, 2022)

被引：1
|
作者：
Graf, R. P.
Fisher, V
Weberpals, J.
机构：
来源：
JAMA NETWORK OPEN | 2022年 / 5卷 / 05期
关键词：
D O I：
10.1001/jamanetworkopen.2022.13901
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol
    Spindler, Nicklas Juel
    Persson, Gitte Fredberg
    Theile, Susann
    Nielsen, Dorte Lisbeth
    Hogdall, Estrid, V
    Al-Farra, Gina
    Hendel, Helle Westergren
    Lorentzen, Torben
    Svane, Inge Marie
    Lindberg, Henriette
    Eefsen, Rikke Lovendahl
    BMJ OPEN, 2023, 13 (01):
  • [42] Circulating tumor DNA-guided treatment decision in metastatic castration-resistant prostate cancer patients: a cost-effectiveness analysis
    Op't Hoog, Catharina J. P.
    Bosman, Sabien J. E.
    Boerrigter, Emmy
    Mehra, Niven
    van Oort, Inge M.
    van Erp, Nielka P.
    Kievit, Wietske
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [43] Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer (vol 5, pg 117, 2011)
    Paller, C. J.
    Antonarakis, E. S.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2011, 5 : 183 - 183
  • [44] Real-world analysis of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence
    Morgans, A. K.
    Divan, H. A.
    Birtle, A. J.
    Dorff, T.
    Ozatilgan, A.
    Graff, J. N.
    ANNALS OF ONCOLOGY, 2019, 30 : 334 - 334
  • [45] Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study
    Axel S. Merseburger
    Eugen Dornstauder
    Carsten-Henning Ohlmann
    Armen Aprikian
    Sophia Junker
    Philipp Hahn
    Andrew Chilelli
    Matthias Stoelzel
    Alexis Serikoff
    Stefan G. Spitzer
    Advances in Therapy, 2025, 42 (4) : 1919 - 1934
  • [46] PSMA PET Index - Introduction of a new imaging quantitative biomarker for assessment of osseous tumor burden in patients with metastatic castration-resistant prostate cancer
    Kroenke, M.
    Bieth, M.
    Tauber, R.
    Retz, M.
    Menze, B.
    Gschwend, J.
    Maurer, T.
    Schwaiger, M.
    Eiber, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S343 - S343
  • [47] AN INDIRECT TREATMENT COMPARISON AND COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE AND ENZALUTAMIDE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER POST CHEMOTHERAPY
    Thompson, Melissa
    Li, Tracy
    Todd, Mary Beth
    Yu, Margaret K.
    Kheoh, Thian
    He, Jianming
    Saadi, Ryan
    JOURNAL OF UROLOGY, 2014, 191 (04): : E810 - E810
  • [48] Association of chemotherapy, enzalutamide, abiraterone, and radium 223 with cognitive function in older men with metastatic castration-resistant prostate cancer (vol 4, e2114694, 2021)
    Alibhai, S. M. H.
    Breunis, H.
    Feng, G.
    JAMA NETWORK OPEN, 2021, 4 (07)
  • [49] Comparative Analysis of 177Lu-PSMA Radioligand Therapy Efficacy in Metastatic Castration-Resistant Prostate Cancer: Impact of Taxane Chemotherapy Precedence
    Nazar, A.
    Srivastava, D.
    Ora, M.
    Barai, S.
    Gambhir, S.
    Pradhan, P.
    Arya, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S672 - S672
  • [50] Comparison of the Epic CTC HRD assay vs. tumor DDR mutations in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)
    Schonhoft, Joseph
    Jendrisak, Adam
    Lee, Jerry
    Rodriguez, Angel
    Sutton, Ramsay
    Wang, Yipeng
    Dittamore, Ryan
    Landers, Mark
    CANCER RESEARCH, 2019, 79 (13)
12345